Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
122 studies found for:    Open Studies | "Niacin"
Show Display Options
Rank Status Study
21 Recruiting Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
Condition: Congenital Heart Disease
Interventions: Dietary Supplement: Vitamin B Complex and Folic Acid;   Dietary Supplement: Iron and Folic Acid;   Dietary Supplement: Folic Acid
22 Recruiting A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris
Interventions: Drug: Tazarotene Cream 0.1%;   Drug: Tazorac®;   Drug: Placebo
23 Recruiting A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Tazarotene Cream 0.05%;   Drug: TAZORAC® (tazarotene) Cream 0.05%;   Drug: Placebo
24 Not yet recruiting Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Condition: Hepatocellular Carcinoma
Interventions: Drug: PDR001;   Drug: Sorafenib
25 Not yet recruiting Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
Condition: HCC
Interventions: Drug: Sorafenib;   Drug: Best Supportive care
26 Recruiting Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Conditions: Hepatocellular Carcinoma;   Recurrence
Intervention: Drug: Sorafenib
27 Recruiting Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Intervention: Biological: Sorafenib plasma concentration 4 weeks after treatment initiation
28 Recruiting TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: SBRT;   Procedure: TACE;   Drug: Sorafenib
29 Recruiting Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib
30 Not yet recruiting Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
Condition: Refractory Solid Tumors
Intervention: Drug: Sorafenib
31 Recruiting Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: HCC
Interventions: Drug: Donafenib;   Drug: Sorafenib
32 Recruiting Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Condition: Hepatocellular Carcinoma
Interventions: Drug: Enzalutamide;   Drug: Enzalutamide with Sorafenib
33 Recruiting Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
Condition: Neoplasms
Intervention: Drug: sorafenib
34 Recruiting A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Condition: Carcinoma, Renal Cell
Interventions: Drug: tivozanib hydrochloride;   Drug: Sorafenib
35 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
36 Recruiting MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Liver Cancer;   HCC
Interventions: Drug: MLN0128;   Drug: MLN0128 (RP2D);   Drug: Sorafenib
37 Recruiting Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Biological: Pexastimogene Devacirepvec (Pexa Vec);   Drug: Sorafenib
38 Recruiting Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib;   Procedure: TACE
39 Recruiting Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Conditions: Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Selinexor;   Drug: Sorafenib
40 Recruiting Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: sorafenib;   Procedure: TACE

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.